Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 3, 2008, Pages 1066-1071

  De Requena, Daniel Gonzalez ^a   Bonora, Stefano ^a   Calcagno, Andrea ^a   D'Avolio, Antonio ^a   Siccardi, Marco ^a   Fontana, Silvia ^a   Milia, Maria Grazia ^b   Sciandra, Mauro ^a   Garazzino, Silvia ^a   Di Garbo, Antonio ^b   Baietto, Lorena ^a   Trentini, Laura ^a   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b AMEDEO DI SAVOIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTATION;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PYRIDINES; PYRONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 40549125612     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01063-07     Document Type: Article

References (19)

1. Back, N. K., A. van Wijk, D. Remmerswaal, M. van Monfort, M. Nijhuis, R. Schuurman, and C. A. Boucher. 2000. In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. AIDS 14:101-102.
2. Baxter, J., J. Schapiro, C. Boucher, V. Kohlbrenner, D. Hall, J. Scherer, and D. Mayers. 2006. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J. Virol. 80:10794-10801.
3. Bonora, S., D. Gonzalez De Requena, A. Calcagno, M. G. Milia, A. D'Avolio, M. Sciandra, S. Garazzino, M. Siccardi, A. Sinicco, and G. Di Perri. 2006. Abstr. 13th Conf. Retrovir. Opportunistic Infect., abstr. 577.
4. Bonora, S., D. Gonzalez de Requena, A. Calcagno, M. G. Milia, A. D'Avolio, M. Sciandra, S. Garazzino, M. Siccardi, A. Sinicco, and G. Di Perri. 2006. Abstr. 7th Int. Workshop Clin. Pharmacol. HIV Ther., abstr. 83.
5. Cahn, P., J. Villacian, A. Lazzarin, C. Katlama, B. Grinsztejn, K. Arasteh, P. Lopez, N. Clumeck, J. Gerstoft, N. Stavrianeas, S. Moreno, F. Antunes, D. Neubacher, and D. Mayers. 2006. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin. Infect. Dis. 43:1347-1356.
6. D'Avolio, A., M. Sciandra, M. Siccardi, L. Baietto, D. Gonzalez de Requena, S. Bonora, and G. Di Perri. 2006. A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. J. Chromatogr. B 848:374-378.
7. Doyon, L., S. Tremblay, L. Bourgon, E. Wardrop, and M. G. Cordingley. 2005. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antivir. Res. 68:27-35.
8. Gathe, J., D. A. Cooper, C. Farthing, D. Jayaweera, D. Norris, G. Pierone, Jr., C. R. Steinhart, B. Trottier, S. L. Walmsley, C. Workman, G. Mukwaya, V. Kohlbrenner, C. Dohnanyi, S. McCallister, D. Mayers, and the RESIST-I Study Group. 2006. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin. Infect. Dis. 43:1337-1346.
9. Gonzalez de Requena, D., O. Gallego, L. Valer, I. Jimenez-Nacher, and V. Soriano. 2004. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res. Hum. Retrovir. 20:275-278.
10. Hicks, C. B., P. Cahn, D. A. Cooper, S. L. Walmsley, C. Katlama, B. Clotet, A. Lazzarin, M. A. Johnson, D. Neubacher, D. Mayers, H. Valdez, and the RESIST Investigator Group. 2006. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368:466-475.
11. MacGregor, T. R., J. P. Sabo, S. H. Norris, P. Johnson, L. Galitz, and S. McCallister. 2004. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin. Trials 5:371-382.
12. Marcelin, A. G., C. Dalban, G. Peytavin, C. Lamotte, R. Agher, C. Delaugerre, M. Wirden, F. Conan, S. Dantin, C. Katlama, D. Costagliola, and V. Calvez. 2004. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 48:4687-4692.
13. Marcelin, A. G., C. Lamotte, C. Delaugerre, N. Ktorza, H. Ait Mohand, R. Cacace, M. Bonmarchand, M. Wirden, A. Simon, P. Bossi, F. Bricaire, D. Costagliola, C. Katlama, G. Peytavin, V. Calvez, and the Genophar Study Group. 2003. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 47: 594-600.
14. McCallister, S., H. Valdez, K. Curry, T. MacGregor, M. Borin, W. Freimuth, Y. Wang, and D. L. Mayers. 2004. A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the non peptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 35:376-382.
15. Naeger, L., J. Zheng, and K. Struble. 2006. Abstr. 13th Conf. Retrovir. Opportunistic Infect., abstr. 639a.
16. Pellegrin, I., D. Breilh, J. M. Ragnaud, S. Boucher, D. Neau, H. Fleury, M. H. Schrive, M. C. Saux, J. L. Pellegrin, E. Lazaro, and M. Vray. 2006. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir. Ther. 11:421-429.
17. Poppe, S. M., D. E. Slade, K. T. Chong, R. R. Hinshaw, P. J. Pagano, M. Markowitz, Ho, D. D., Mo, H., R. R. Gorman III, T. J. Dueweke, S. Thaisrivongs, and W. G. Tarpley. 1997. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 41:1058-1063.
18. Turner, S. R., J. W. Strohbach, R. A. Tommasi, P. A. Aristoff, P. D. Johnson, H. I. Skulnick, L. A. Dolak, E. P. Seest, P. K. Tomich, M. J. Bohanon, M. M. Horng, J. C. Lynn, K. T. Chong, R. R. Hinshaw, K. D. Watenpaugh, M. N. Janakiraman, and S. Thaisrivongs. 1998. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. 41:3467-3476.
19. Valdez, H., S. McCallister, V. Kohlbrenner, and D. Mayers. 2005. Abstr. 3rd IAS Conf. HIV Pathogenesis Treatment, abstr. WeOa0205.